Bayer has agreed to pay $7.25 billion to settle thousands of lawsuits alleging its Roundup weed killer caused non-Hodgkin lymphoma, marking one of the largest product liability settlements in U.S. history. Announced on February 17, 2026, the proposed class-action settlement covers more than 65,000 pending claims in federal and state courts, with individual payouts ranging from $6,000 to $165,000 depending on factors like exposure type, age at diagnosis, and cancer severity. A agricultural worker diagnosed with aggressive NHL before age 60, for instance, could receive roughly $165,000 — while a residential user diagnosed after age 77 might see closer to $10,000.
The deal is far from finalized. A Missouri circuit court granted preliminary approval on March 4, 2026, but lawyers representing nearly 20,000 plaintiffs have already objected, arguing the settlement was negotiated without adequate input from all parties. Meanwhile, the U.S. Supreme Court is set to hear oral arguments on April 27, 2026 in a related preemption case that could reshape the entire litigation landscape. This article breaks down who qualifies, how much claimants can expect, the opt-out deadline you cannot afford to miss, and why the Supreme Court case matters more than most people realize.
Table of Contents
- How Did the $7.25 Billion Roundup Cancer Settlement Come Together?
- Who Is Eligible for Roundup Settlement Payouts — and Who Is Not?
- What Will Individual Roundup Settlement Payouts Actually Look Like?
- Should You Stay in the Settlement or Opt Out?
- Why the Supreme Court Case Could Change Everything
- The Pushback From Plaintiffs’ Attorneys
- What Happens Next and What Claimants Should Watch
- Conclusion
- Frequently Asked Questions
How Did the $7.25 Billion Roundup Cancer Settlement Come Together?
The Roundup litigation has been building since 2015, when the International Agency for Research on Cancer classified glyphosate — the active ingredient in Roundup — as “probably carcinogenic to humans.” Since then, more than 125,000 plaintiffs have lodged legal claims against Bayer, which acquired Monsanto and its Roundup product line in 2018. Early jury verdicts went badly for Bayer, with several juries awarding hundreds of millions of dollars to individual plaintiffs, though those amounts were later reduced on appeal. This $7.25 billion settlement is structured as a 21-year long-term compensation program, funded through annual payments by Bayer rather than a single lump sum. That structure matters because it allows Bayer to manage the financial hit over time while theoretically ensuring money remains available for claimants diagnosed with NHL years from now.
Notably, Bayer is not admitting liability and continues to maintain that glyphosate-based Roundup does not cause cancer — a position that puts the company at odds with thousands of cancer patients and a significant body of epidemiological research, but aligns with the U.S. Environmental Protection Agency’s own assessment. Compare this to Bayer’s previous attempt at a global settlement in 2020, when the company set aside roughly $10.9 billion to resolve Roundup claims. That effort stalled partly because it failed to adequately address future claimants. This new deal attempts to solve that problem by covering people who receive an NHL diagnosis within the next 16 years, though whether that timeline is sufficient remains an open question.
Who Is Eligible for Roundup Settlement Payouts — and Who Is Not?
eligibility hinges on a few specific criteria. You must have been living in the United States on March 4, 2026, regardless of citizenship status. You must have had contact with Roundup or a qualifying glyphosate-based product in the U.S. before February 17, 2026. And you must either currently have a non-Hodgkin lymphoma diagnosis or receive one within the next 16 years. The definition of “contact” is broader than many people assume — it includes not just personal application of the product, but also purchasing it, paying for someone else to apply it, participating in or witnessing its application, or otherwise having reason to know you were exposed.
However, if you were diagnosed with a different type of cancer — say, leukemia or bladder cancer — this settlement does not cover you, even if you believe Roundup exposure was a contributing factor. The deal is specifically limited to non-Hodgkin lymphoma. Additionally, if you were not living in the U.S. on the preliminary approval date or your exposure occurred entirely outside the country, you are excluded. These limitations will leave some people who genuinely believe they were harmed by Roundup without recourse through this particular settlement, though individual lawsuits remain an option for those who opt out. It is also worth flagging that class members are automatically included in the settlement unless they take affirmative steps to opt out. If you do nothing, you are bound by the terms of the deal and waive your right to sue Bayer individually over Roundup-related NHL claims.
What Will Individual Roundup Settlement Payouts Actually Look Like?
The payout structure is tiered, and the differences between tiers are substantial. At the top end, agricultural and industrial workers who had long-term occupational exposure and were diagnosed with aggressive forms of non-Hodgkin lymphoma before age 60 can expect approximately $165,000. At the bottom end, individuals diagnosed at age 78 or older may receive roughly $10,000. Residential users — the millions of homeowners who sprayed Roundup on their driveways and garden beds — diagnosed between ages 60 and 77 fall in the middle at approximately $20,000. To put those numbers in perspective, consider a hypothetical case: a 55-year-old farm worker in Iowa who sprayed Roundup commercially for 20 years and was diagnosed with diffuse large B-cell lymphoma. Under the settlement, that person would likely qualify for a payout near the $165,000 ceiling. Now compare that to a 70-year-old suburban homeowner in Florida who used Roundup on weekends for a decade and was diagnosed with follicular lymphoma.
That person might receive around $20,000. Both have cancer. Both used the same product. But the settlement values their claims very differently based on exposure intensity and age. Critics have pointed out that even the top-tier payout of $165,000 is modest compared to what some plaintiffs have won at trial. Dewayne Johnson, the first plaintiff to take Bayer to trial in 2018, was initially awarded $289 million (later reduced to $20.5 million). The settlement amounts reflect the reality that mass settlements always involve significant discounting — the certainty of a guaranteed payout versus the risk and delay of individual litigation.
Should You Stay in the Settlement or Opt Out?
This is the most consequential decision facing Roundup claimants right now, and the opt-out deadline is June 4, 2026. If you remain in the class, you receive your designated payout and permanently give up the right to sue Bayer individually. If you opt out, you preserve your right to file your own lawsuit — but you also take on the risk that Bayer could prevail at trial or that the Supreme Court could effectively shut down failure-to-warn claims entirely. The tradeoff looks different depending on your circumstances. For someone with a strong individual case — extensive documented exposure, aggressive cancer, clear medical records, and access to experienced trial counsel — opting out and pursuing a standalone lawsuit could yield a far larger recovery than the settlement offers.
Some Roundup trial verdicts have reached into the tens or hundreds of millions of dollars before being reduced. But trials are expensive, slow, and uncertain. A plaintiff who opts out might wait years for resolution and could ultimately receive nothing. There is also a structural wildcard: Bayer reserves the right to walk away from the entire settlement if too many people opt out. If that happens, everyone is back to square one. Plaintiffs’ attorneys are watching opt-out numbers closely because a mass exodus could collapse the deal and leave all claimants — including those who wanted the settlement — in limbo.
Why the Supreme Court Case Could Change Everything
The case of Durnell v. Monsanto, set for oral arguments on April 27, 2026, poses an existential threat to Roundup litigation as we know it. The central legal question is whether the Federal Insecticide, Fungicide, and Rodenticide Act preempts state-level failure-to-warn claims when the EPA has not required a cancer warning on the product label. In plain language: if the EPA says Roundup’s label does not need a cancer warning, can state courts still hold Bayer liable for failing to warn consumers about cancer risk? Bayer’s argument is straightforward — the EPA approved Roundup’s labeling without requiring a cancer warning, and federal law should override any state-level attempt to impose different labeling requirements through litigation. Two federal appellate courts have rejected this preemption argument, but the Third Circuit ruled in Bayer’s favor, creating a circuit split that the Supreme Court agreed to resolve.
A decision is expected in the second half of June 2026. If the Supreme Court sides with Bayer, it could effectively gut the legal basis for most pending Roundup lawsuits. Failure-to-warn claims are the backbone of the litigation, and a ruling that federal pesticide law preempts those claims would make it dramatically harder for plaintiffs to prevail at trial. That possibility is one reason why some plaintiffs’ attorneys are advising clients to stay in the settlement rather than gamble on an uncertain legal future. Conversely, if the Court rules against Bayer, it removes a major defense and could embolden even more plaintiffs to opt out and pursue larger individual recoveries.
The Pushback From Plaintiffs’ Attorneys
Not everyone in the legal community thinks this settlement is a good deal. Lawyers from 14 firms representing nearly 20,000 Roundup plaintiffs have formally objected, arguing that the $7.25 billion deal was negotiated without sufficient input from all parties and that the approval process is being rushed.
Their concern is not abstract — these attorneys believe their clients’ claims are worth significantly more than what the settlement offers and that the compressed timeline for preliminary approval did not allow adequate scrutiny of the deal’s terms. This kind of intra-plaintiff friction is not unusual in mass tort litigation, but the scale of the opposition here is notable. When nearly 20,000 claimants are represented by attorneys who actively oppose the settlement, it raises legitimate questions about whether the deal truly serves the interests of the entire class or primarily benefits the law firms that negotiated it and the defendant seeking closure.
What Happens Next and What Claimants Should Watch
The final approval hearing is scheduled for July 9, 2026, in Missouri’s 22nd Judicial Circuit Court. Between now and then, several things will shape the outcome. The Supreme Court’s decision in Durnell, expected in late June, will either strengthen or weaken the settlement’s appeal to claimants.
Opt-out numbers, due by June 4, will determine whether Bayer proceeds with the deal or pulls out. And the objecting attorneys will have their chance to argue that the settlement terms are inadequate. For anyone affected by this litigation — whether you are a current NHL patient, a longtime Roundup user who has not been diagnosed, or a family member trying to understand the options — the next three months are critical. The decisions made in courtrooms and by individual claimants between now and July will determine whether this $7.25 billion settlement becomes the final chapter of the Roundup saga or merely another installment in a legal fight that has already lasted more than a decade.
Conclusion
Bayer’s $7.25 billion Roundup settlement represents a massive financial commitment but remains deeply contested. The deal offers guaranteed payouts ranging from $6,000 to $165,000 for people diagnosed with non-Hodgkin lymphoma who were exposed to Roundup in the United States, with a 21-year payment structure and coverage for future diagnoses over the next 16 years. Preliminary court approval has been granted, but significant opposition from plaintiffs’ attorneys and the looming Supreme Court preemption case make the outcome far from certain.
If you or someone you know has been diagnosed with NHL and has a history of Roundup exposure, the most important immediate action is to understand the June 4, 2026 opt-out deadline and make an informed decision before it passes. Consult with a qualified attorney who can evaluate your specific circumstances — your exposure history, diagnosis, and individual case strength — before deciding whether to accept the settlement or preserve your right to litigate independently. Doing nothing means you are in the settlement by default, and once the opt-out window closes, that decision is irreversible.
Frequently Asked Questions
How do I know if I qualify for the Roundup settlement?
You must have been living in the U.S. on March 4, 2026, had contact with Roundup or a qualifying glyphosate product in the U.S. before February 17, 2026, and either have a current non-Hodgkin lymphoma diagnosis or receive one within the next 16 years. Contact includes personal use, purchasing the product, witnessing its application, or otherwise having reason to know of exposure.
How much money will I receive from the Roundup settlement?
Payouts range from $6,000 to $165,000. The amount depends on your type of exposure (agricultural/industrial versus residential), your age at diagnosis, and the severity of your cancer. Agricultural workers diagnosed with aggressive NHL before age 60 receive the highest amounts, while those diagnosed at age 78 or older receive approximately $10,000.
What is the deadline to opt out of the Roundup settlement?
The opt-out deadline is June 4, 2026. If you do not opt out by that date, you are automatically included in the settlement and waive your right to file an individual lawsuit against Bayer over Roundup-related NHL claims.
What happens if the Supreme Court rules in Bayer’s favor in Durnell v. Monsanto?
If the Supreme Court rules that federal pesticide law preempts state failure-to-warn claims, it could severely undermine the legal basis for individual Roundup lawsuits. That would make the settlement more attractive by comparison, since plaintiffs who opted out might find it much harder to win at trial. A decision is expected in the second half of June 2026.
Can I file a claim if I haven’t been diagnosed with cancer yet?
Yes. The settlement covers future diagnoses of non-Hodgkin lymphoma made within the next 16 years, provided you meet the other eligibility requirements regarding U.S. residency and Roundup exposure. However, you cannot file a claim until you actually receive a diagnosis.
Is Bayer admitting that Roundup causes cancer?
No. Bayer explicitly states that it is not admitting liability and maintains that glyphosate-based Roundup does not cause cancer. The settlement is framed as a business decision to resolve ongoing litigation, not as an acknowledgment of wrongdoing.